Endoscopic Mucosal Injection Versus Ultrasound-Guided Injection of Triamcinolone to Treat Subglottic Stenosis

Launched by CHINA-JAPAN FRIENDSHIP HOSPITAL · Feb 17, 2024

Keywords

ClinConnect Summary

This clinical trial is comparing two different methods of treating subglottic stenosis, which is a narrowing of the airway that can make it hard to breathe and cause hoarseness. The study will randomly assign participants to receive either an endoscopic mucosal injection or an ultrasound-guided injection of a medication called triamcinolone. Researchers are looking at how effective each method is, any side effects that might occur, the costs involved, and how much hospital care is needed for each treatment.

To participate in this trial, individuals must be between 65 and 74 years old and have been diagnosed with subglottic stenosis, experiencing symptoms like difficulty breathing or hoarseness. However, some people cannot join the study, such as those with severe heart or lung problems, those who are pregnant or breastfeeding, or those who have had recent treatments with the same medication. Participants can expect close monitoring and care during the trial as researchers work to determine which treatment option is better for patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1: "Diagnosed with subglottic stenosis through laryngoscopic examination or imaging studies such as CT."
• • 2: "Experiencing symptoms related to subglottic stenosis, such as breathing difficulties, hoarseness, etc."
• Exclusion Criteria:
• • 1: "Severe cardiopulmonary dysfunction, patients extremely debilitated and unable to tolerate the procedure."
• • 2: "Patients allergic to lidocaine, midazolam, triamcinolone, or any of their components."
• • 3: "Pregnant or lactating women."
• • 4: "Unstable angina, congestive heart failure, severe bronchial asthma."
• • 5: "Severe hypertension and arrhythmias, hemodynamically unstable, and severe respiratory failure (PaO2 \<60mmHg after oxygen therapy or mechanical ventilation)."
• • 6: "Known coagulation dysfunction, inability to stop anticoagulants, antiplatelet agents, aspirin, or nonsteroidal anti-inflammatory drugs before treatment."
• • 7: "Patients do not agree to participate in this study."
• • 8: "Participation in other studies within the last three months and not withdrawn or concluded, or having received triamcinolone treatment less than 1 month ago."
• • 9: "Researchers believe there are any circumstances making the patient unsuitable for inclusion."